Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Attention Thanekar! TMC Announces 12-Hour Water Cut In GB Road, Patlipada & Several Areas In City On June 18
FDs Losing Appeal, Investors Turning To Higher Returns; Here's Why The Trend Is Changing
Israel-Iran War: Soap, Oil, Biscuits Prices In India To Skyrocket; Raw Materials To Become Expensive, Say FMCG Companies
Mumbai Crime News: Juhu Hookah Parlour Busted For Illegal Activities; 45 People, Including 5 Young Women, Booked
